The role of these cytokines in acting, uniquely among related IL-1 family members, to imprint a colitogenic phenotype on CD4+ T cells provides further validation towards ongoing efforts aimed at targeting this pathway in IBD and also indicates that such strategies may be particularly beneficial during the earliest phases of disease onset. Here, CD4 is linked to inflammatory bowel disease.